These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 16499283

  • 21. [A kinetic study of gamma interferon production in herpes simplex virus-1 DNA prime-protein boost regimen comparing to DNA or subunit vaccination].
    Arefian E, Bamdad T, Soleimanjahi H, Akhood MR, Parsania M, Ghaemi A.
    Mol Biol (Mosk); 2009; 43(3):422-8. PubMed ID: 19548528
    [Abstract] [Full Text] [Related]

  • 22. Immunity in latent Herpes simplex virus infection.
    Bystrická M, Russ G.
    Acta Virol; 2005; 49(3):159-67. PubMed ID: 16178513
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. DNA vaccine-encoded glycoprotein B of HSV-1 fails to protect chronic morphine-treated mice against HSV-1 challenge.
    Jamali A, Roostaee MH, Soleimanjahi H, Ghaderi Pakdel F, Bamdad T.
    Comp Immunol Microbiol Infect Dis; 2007 Mar; 30(2):71-80. PubMed ID: 17126902
    [Abstract] [Full Text] [Related]

  • 25. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.
    Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F.
    FEMS Immunol Med Microbiol; 2008 Oct; 54(1):18-26. PubMed ID: 18647350
    [Abstract] [Full Text] [Related]

  • 26. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ, Truong NR, Smith JB, Bertram K, Cunningham AL.
    Methods Mol Biol; 2020 Oct; 2060():31-56. PubMed ID: 31617171
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D.
    Awasthi S, Shaw C, Friedman H.
    Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection.
    Mastrolorenzo A, Tiradritti L, Salimbeni L, Zuccati G.
    Int J STD AIDS; 1995 Dec; 6(6):431-5. PubMed ID: 8845402
    [Abstract] [Full Text] [Related]

  • 33. Status of vaccine research and development of vaccines for herpes simplex virus.
    Johnston C, Gottlieb SL, Wald A.
    Vaccine; 2016 Jun 03; 34(26):2948-2952. PubMed ID: 26973067
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Genital herpes vaccines--cause for cautious optimism.
    Haddow LJ, Mindel A.
    Sex Health; 2006 Mar 03; 3(1):1-4. PubMed ID: 16607967
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
    Quenelle DC, Collins DJ, Marciani DJ, Kern ER.
    Vaccine; 2006 Mar 06; 24(10):1515-22. PubMed ID: 16288820
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2.
    Mori I, Liu B, Goshima F, Ito H, Koide N, Yoshida T, Yokochi T, Kimura Y, Nishiyama Y.
    Microbes Infect; 2005 Dec 06; 7(15):1492-500. PubMed ID: 16054416
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.